http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015098969-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a9727f1d4e6a16ee58430f2bb18e60b3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5094 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61J1-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61J1-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2013-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be444c0c72e4cb4ded49298f45451581 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ace7281c9ed1b44854403eb3a5778fef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_addd80f3cf2750b169769646fcb3ddbf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e571242fe7878179d2f1e7a19ae7467 |
| publicationDate | 2015-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2015098969-A1 |
| titleOfInvention | Alternaria peptides |
| abstract | Pharmaceutical formulations, which may be used for preventing or treating allergy to moulds of the Alternaria and/or Cladosporium genus, comprising a pharmaceutically acceptable carrier or diluent and a polypeptide or a pharmaceutically acceptable salt thereof selected from at least three of: (a) a polypeptide comprising the amino acid sequence of WSWKIGPAIATGNT (Alt28; SEQ ID NO: 101) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (b) a polypeptide comprising the amino acid sequence of KYRRVVRAGVKVAQTAR (Alt34A; SEQ ID NO: 107) or a T cell epi tope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (c) a polypeptide comprising the amino acid sequence of KYAGVFVSTGTLGGG (SEQ ID NO: 112) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (d) a polypeptide comprising the amino acid sequence of AEVYQKLKALAKKTYGQ (Alt13A; SEQ ID NO: 83) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (e) a polypeptide comprising the amino acid sequence of SLGFNIKATNGGTLD (Alt01A; SEQ ID NO: 60) or a T cell epi tope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (f) a polypeptide comprising the amino acid sequence of SAKRMKVAFKLDIEK (Alt06; SEQ ID NO: 72) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (g) a polypeptide comprising the amino acid sequence of DITYVATATLPNYCR (SEQ ID NO: 111) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; and (h) a polypeptide comprising the amino acid sequence of GWGVMVSHRSGET (Alt14; SEQ ID NO: 84) or a T cell epi tope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; wherein a T cell epitope-containing variant sequence of a said amino acid sequence is said amino acid sequence having up to seven amino acid modifications, each of which is independently a deletion, substitution or insertion, and each polypeptide is up to 30 amino acids in length. |
| priorityDate | 2012-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 198.